Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1775-1781

  Chalmers, J ^a   Hunter, J E ^a   Robertson, S J ^a   Baird, J ^a   Martin, M ^a   Franks, C I ^a   Whately Smith, C R ^b   Mariz, S ^c   Campbell, I W ^a  

^a VICTORIA HOSPITAL   (United Kingdom)

^b Hunton Bridge   (United Kingdom)

^c Takeda Global Research and Development Centre (Europe) Ltd   (United Kingdom)

Author keywords

Combination therapy; Glycaemic control; Metformin pioglitazone; Type 2 diabetes

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; REPAGLINIDE;

ADULT; AGED; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE TITRATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL ASSESSMENT; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 34548118274     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210606     Document Type: Article

References (20)

1. Fox KM, Gerber Pharmd RA, Bolinder B, et al. Prevalence of inadequate glycaemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-95
2. 1c following successful initial metformin therapy. Diabetes Care 2006;29:504-9
3. Turner RC, Cull CA, Frighi V, et al. Glycaemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement of multiple therapies (UKPDS 49). J Am Med Assoc 1999;281:2005-12
4. Campbell IW. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol 2000;7:625-31
5. Campbell IW, Mariz S. β-cell preservation with thiazolidine-diones. Diabetes Res Clin Pract 2007;76:163-76
6. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000;22:1395-409
7. Derosa G, Cicero AFG, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a 12-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54
8. Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093-104
9. Derosa G, Cicero AFG, Gaddi AV, et al. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. Clin Ther 2005;27:1383-91
10. Ginis AA, Karamanos B, Charalampidou E, et al. Evaluation of changes of glycaemic control and lipid parameters in patients with T2DM after one year of treatment with pioglitazone in combination with metformin or sulfonylurea in a Greek observational study [Abstract]. Diabetologia 2006;49(Suppl 1):490
11. Charbonnel B, Scheen A. Combination therapy with pioglitazone and either metformin or sulfonylurea: glycemic results from PROactive [Abstract]. Diabetes 2006;55(Suppl 1):A478
12. Perez A, Spanheimer R, Khan M. Glycaemic control in patients with type 2 diabetes: the effects of pioglitazone vs glyburide in a 3-year randomized double-blind trial [Abstract]. Diabetologia 2006;49(Suppl 1):490
13. Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
14. Nathan DM, Buse JB, Davidson MB, et al; Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21
15. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care 2003;26:1852-5
16. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995-1000
17. Bell DS, Ovalle F. Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes. Diabetes Obes Metab 2004;6:363-6
18. Campbell IW. The role of metformin and pioglitazone in early combination treatment of type 2 diabetes mellitus. Br J Diabetes Vasc Dis 2006;6:207-15
19. Ristic S, Collober-Maugeais C, Pecher E, et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006;23:757-62
20. Gerich J, Raskin P, Jean-Louis L, et al. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005;28:2093-9